Case Studies – The Catapult Network

Browse Catapults

Case Studies from across the Catapults

Search

Themes

Cross-Catapult (2),
Cell and Gene Therapy (16),
Compound Semiconductor Applications (13),
Connected Places (14),
Digital (14),
Energy Systems (14),
High Value Manufacturing (17),
Medicines Discovery (15),
Offshore Renewable Energy (14),
Satellite Applications (14),

Catapults (Reset)

Medicines Discovery

alt=

Portfolio | PACE

To address the global threat of AMR, PACE is providing funding and support for a portfolio of early-stage projects.

Medicines Discovery

Portfolio | PACE

To address the global threat of AMR, PACE is providing funding and support for a portfolio of early-stage projects.

Medicines Discovery

How do we supercharge and sustain skills in UK Life Sciences?

Medicines Discovery Catapult is reshaping drug discovery for patient benefit by transforming great UK science into better treatments through partnership. The life sciences industry is critical to the UK’s health, wealth, and resilience. Attracting, recruiting, training, and retaining a skilled workforce is key to ongoing success in this critical sector.

Medicines Discovery

Bolstering the North West’s position as a life science powerhouse

Medicines Discovery Catapult is driving regional growth in the North West of England, supporting the region’s fast-growing and increasingly significant life science industry.

Medicines Discovery

alt=

Transforming UK medical imaging

The Medicines Discovery Catapult is working to ensure the UK remains a world leader in Positron Emission Tomography (PET) Imaging, a data-rich non-invasive imaging modality that offers huge potential across the life sciences and is highly amenable to advances in AI.

Medicines Discovery

alt=

Alchemab Therapeutics secures private funding for new treatments following collaboration

In 2021 Alchemab and Medicines Discovery Catapult (MDC) collaborated on a Huntington’s disease focussed project, which supported Alchemab in securing significant private investment.

Medicines Discovery

alt=

The Psychiatry Consortium – exploring new treatments for mental health conditions

Medicines discovery for challenging diseases requires a collaborative approach with a patient focus. In 2019 the Medicines Discovery Catapult established the Psychiatry Consortium as one of its patient focussed partnerships. It is a strategic collaboration of two leading medical research charities and seven international pharmaceutical companies, focusing on the unmet therapeutic needs of people living with mental health conditions.

Medicines Discovery

The Psychiatry Consortium – exploring new treatments for mental health conditions

Medicines discovery for challenging diseases requires a collaborative approach with a patient focus. In 2019 the Medicines Discovery Catapult established the Psychiatry Consortium as one of its patient focussed partnerships. It is a strategic collaboration of two leading medical research charities and seven international pharmaceutical companies, focusing on the unmet therapeutic needs of people living with mental health conditions.

Medicines Discovery

alt=

Launch of a drug discovery consortium to address the unmet therapeutic needs of people living with mental health conditions

The Psychiatry Consortium is a £4 million international collaboration between seven global pharmaceutical companies and two leading medical research charities, convened and managed by Medicines Discovery Catapult, to support high-value drug discovery projects that address the unmet therapeutic needs of people living with mental health conditions, including psychiatric symptoms associated with dementia.

Medicines Discovery

Launch of a drug discovery consortium to address the unmet therapeutic needs of people living with mental health conditions

The Psychiatry Consortium is a £4 million international collaboration between seven global pharmaceutical companies and two leading medical research charities, convened and managed by Medicines Discovery Catapult, to support high-value drug discovery projects that address the unmet therapeutic needs of people living with mental health conditions, including psychiatric symptoms associated with dementia.

Medicines Discovery

Highlighting the role of women in science and innovation

By championing innovative life science technology and new approaches, Medicines Discovery Catapult is supporting UK innovators to succeed. Medicines Discovery Catapult recognises that diversity in the workforce underpins the creative and innovative thinking essential for success in this sector.

Medicines Discovery

International biobank provides database for cancer researchers worldwide

Medicines Discovery Catapult collaborated with Manchester University to create a sustainable model for a biorepository providing a critical data for researchers investigating patient side-effects from radiotherapy.

Medicines Discovery

alt=

Innovative treatments for a longer healthy, independent life

Figures show that we are spending more of our lives in poor health. In response, a national network is bringing together scientific expertise from across the UK to shed new light on the ageing process and help us stay healthy for longer.

Medicines Discovery

alt=

Mobilising national high scale COVID-19 testing

In March 2020, the UK government announced the launch of a national testing effort to support the UK’s fight against coronavirus via the establishment of a network of high-scale testing laboratories, known as “Lighthouse Labs”.

Medicines Discovery

alt=

Developing new treatments to prevent thrombosis

LUNAC Therapeutics, a UK based drug discovery company, together with the Medicines Discovery Catapult and the University of Leeds, are working on the development of an innovative first-in-class anticoagulant treatment drug with minimal bleeding risk.

Medicines Discovery

Developing new treatments to prevent thrombosis

LUNAC Therapeutics, a UK based drug discovery company, together with the Medicines Discovery Catapult and the University of Leeds, are working on the development of an innovative first-in-class anticoagulant treatment drug with minimal bleeding risk.

Medicines Discovery

alt=

Discovery Services platform boosts UK life sciences R&D and international competitiveness

The Medicines Discovery Catapult Virtual R&D Discovery Services platform helps match UK SMEs to access medicines and drug discovery services and state-of-the-art equipment, enabling deeper market penetration and access to a wider network of customers.

Medicines Discovery

Discovery Services platform boosts UK life sciences R&D and international competitiveness

The Medicines Discovery Catapult Virtual R&D Discovery Services platform helps match UK SMEs to access medicines and drug discovery services and state-of-the-art equipment, enabling deeper market penetration and access to a wider network of customers.

Page 1 of 1